Fasting Glucose is a Useful Indicator for Cerebrovascular Risk in Non–Diabetic Koreans: Association With Oxidative Stress and Inflammation

Jae Hyang Lee¹², So Ra Yoon¹, Ga Yoon Na¹, Mira Jun¹, Mok-Ryeon Ahn¹, Jae-Kwan Cha², Oh Yoen Kim*¹

¹Department of Food Science Nutrition, Brain Busan 21 project, Dong-A University, Busan, 49315 Korea
²Department of Neurology, Busan–Ulsan Regional Cardiocerebrovascular Center, Dong-A University Hospital, College of Medicine, Busan, 49201 Korea

Diabetes and impaired fasting glucose are associated with incidence of cerebro-/cardio-vascular diseases. This study hypothesized that fasting glycemic status may reflect cerebrovascular risk in non-diabetic Koreans. Fasting glycemic status, lipid profiles, oxidative stress, and inflammation markers were measured in non-diabetic subjects (healthy controls, n = 112 and stroke n = 41). Systolic blood pressure, fasting glucose, glycated hemoglobin (HbA1C), triglycerides, high sensitivity C-reactive protein (hs-CRP), interleukin-6, and tumor necrosis factor-alpha were higher, and high density lipoprotein (HDL)-cholesterols were lower in patients with stroke than healthy controls. Fasting glucose positively correlated with hs-CRP, interleukin-6, tumor necrosis factor-alpha, oxidized low density lipoprotein (LDL) and malondialdehyde. The significances continued or at least turned to a trend after adjustments for confounding factors. Multiple regression analyses revealed that fasting glucose was mainly associated with cerebrovascular risk ($\beta$-coefficient = 0.284, p < 0.0001) together with systolic blood pressure, total cholesterol, hs-CRP, body mass index, dietary poly unsaturated fatty acid/saturated fatty acid (PUFA/SFA), and HbA1C ($r^2 = 0.634$, p = 0.044). The subjects were subdivided by their fasting glucose levels [normal fasting glucose: 70–99 mg/dL, n = 91 [NFG-control] and n = 27 [NFG-stroke]; higher fasting glucose: 100–125 mg/dL, n = 21 [HFG-control] and n = 14 [HFG-stroke]). In both controls and stroke patients, HFG groups show higher triglyceride, total- and LDL-cholesterol and lower HDL-cholesterol than NFG groups. Control–HFG group showed significantly higher levels of oxidative stress and inflammation than control–NFG group. Stroke–HFG group also showed significantly higher inflammatory levels than stroke–NFG group, moreover the highest among the groups. Additionally, stroke–NFG group consumed higher PUFA/SFA than stroke–HFG group. Fasting glucose may be a useful indicator for cerebrovascular risk in non-diabetic individuals which may be mediated by oxidative stress and inflammation status.

Key Words: Fasting glucose, Oxidative stress, Inflammation, Cerebrovascular risk, Non-diabetes

Received January 4, 2016
Revised January 12, 2016
Accepted January 13, 2016

© 2016 The Korean Society of Clinical Nutrition

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

According to the World Health Organization and the Centers for Disease Control and Prevention, the prevalence of cerebrovascular diseases is increasing progressively, resulting in the increased costs for treatment and management of the diseases [1-3]. The Statistics Korea reported that cerebrovascular diseases, particularly cerebrovascular disease, had the highest mortality rate for a single disease in 2013 [4]. The majority of cerebrovascular diseases are caused by risk factors that can be controlled, treated, or modified (i.e. hypertension, hyperlipidemia, hyperglycemia, physical inactivity, unhealthy and unbalanced diet, heavy smoking, and obesity) [1-3]. However, there are some major risk factors that cannot be controlled (i.e. age, gender, and family history) [1-3].

Many prospective, longitudinal cohort studies and cross-sectional studies have reported a relationship between glycemic status and the risk of stroke, independent of other prognostic factors [5-8]. For example, Tanne et al. [5] reported that fasting glucose is closely associated with the risk of ischemic cerebrovascular events (ICEs), which showed a J-shaped association: the risk for ICEs was increased in the individuals with an fasting plasma glucose (FPG) level >100 mg/dL as well as in those with an FPG level <90 mg/dL than in those with a FPG level of 90-99 mg/dL [5]. Nielson et al. showed that the prevalence of ischemic attack or stroke was significantly higher in the individuals with impaired fasting glucose status compared with that in those with normal blood glucose levels [6].

A possible mechanism by which higher fasting glucose levels affect cerebrovascular risk may be explained by several experimental reports showing that higher blood glucose levels result in the production of advanced glycation end products (AGEs) in the blood stream [9-14]. Increased AGEs may lead to the intracellular generation of reactive oxygen species (ROS) and oxidative stress, resulting in elevated inflammatory responses and consequent endothelial malfunction [9-14]. However, there are few studies on the relationship between fasting glycemic status and cerebrovascular risk in non-diabetic individuals.

Therefore, we hypothesized that fasting glycemic status even in non-diabetic condition may sensitively reflect cerebrovascular risk in non-diabetic Koreans. To test the hypothesis, we aimed to investigate the relationship of fasting glycemic status to cerebrovascular risk parameters including classical parameters, oxidative and inflammatory markers in non-diabetic Koreans (healthy control and stroke patients).

Materials and Methods

Subjects and study design

All the study subjects were recruited from Dong-A University Hospital between January and March 2014. Patients with stroke were recruited from the Busan-Ulsan Regional Cardiovascular Center at Dong-A University Hospital. They were all diagnosed for stroke and were under management by routine check-up every 2 months. The average time since being diagnosed for stroke was 4.66 ± 0.85 years. They did not have any diagnosis of diabetes, renal disease, liver disease, thyroid disease, or acute or chronic inflammatory disease. Control individuals were recruited during routine health check-ups at the Health Promotion Center at Dong-A University Hospital. They did not have any history of stroke or diabetes. Exclusion criteria for the control individuals were orthopedic limitations, ~10% weight loss/gain over the previous 6 months, or any diagnosis of vascular disease, cancer (clinically or by anamnesis), renal disease, liver disease, thyroid disease, or acute or chronic inflammatory disease. In addition, subjects with fasting glucose levels less than 125 mg/dL were included in the analysis. The study participants were interviewed regarding their smoking and drinking behavior and medications. All the participants were provided with detailed information of the study and provided written informed consent. The study protocol was approved by the Institutional Review Board of Dong-A University and was carried out in accordance with the Helsinki Declaration. Finally, 41 patients with stroke and 112 control individuals were included in the study.

Anthropometric parameters, blood pressure, and blood collection

Height and body weight were measured. Body mass index (BMI) was calculated as body weight divided by height (kg/m²). Blood pressure (BP) was obtained from the left arm of seated individuals with an automatic BP monitor (HEM-7220, OMRON, Matsuoka, Japan) after a short rest. After an overnight fast, venous blood specimens were collected in EDTA-treated tubes or plain tubes. The tubes were immediately placed on ice until they arrived at the analytical laboratory (1–3 h). The blood specimens were separated into plasma and serum and stored at -80°C until analysis.

Fasting glucose, glycated hemoglobin (HbA1C) and lipid profiles

Fasting glucose was measured using a glucose oxidase method (Glucose Analyzer Beckman Instruments, Irvine, CA,
USA) as described in a previous report [15]. Glycated hemoglobin (HbA1C) was measured using Variant II Turbo HbA1C kit-2.0 (Bio-Rad, Hercules, CA, USA) ON Variant (Variant II TURBO, Bio-Rad, Hercules, CA, USA). Serum total cholesterol, triglyceride, and low-density lipoprotein (LDL) cholesterol levels were measured using commercially available kits on a Hitachi 7150 Auto-analyzer (Hitachi Ltd., Tokyo, Japan), as described previously [16]. The intra-assay and inter-assay coefficients of variance in triglyceride level were 1.50% and 1.80%, respectively, and those of variance in total cholesterol level were 0.80% and 1.70%, respectively. After precipitating the serum chylomicrons, LDL-cholesterol, and very low-density lipoprotein with dextran sulfate-magnesium, the high-density lipoprotein (HDL) cholesterol left in the supernatant was measured by a previously described enzymatic method [16].

**Serum high-sensitivity C-reactive protein, plasma interleukin-6, and tumor necrosis factor-α**

Serum high-sensitivity C-reactive protein (hs-CRP) was measured with an ADVIA 1650 system (Bayer, Tarrytown, NY, USA) using a commercially available, hs-CRP-Latex(II) X2 kit (Seiken Laboratories Ltd., Tokyo, Japan) that allows the detection of CRP in the range of 0.001–31 mg/dL, as described in a previous report [16]. The intra-assay and inter-assay coefficients of variance were 1.87% and 1.89%, respectively. Plasma concentrations of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured using the Quantikine® HS ELISA Kit (RnD systems, Inc., Minneapolis, MN, USA) according to the manufacturer’s instructions. The resulting color reaction was measured using the iMark™ microplate absorbance reader (Bio-Rad Laboratories, Hercules, CA, USA). The wavelength correction was set to 490 nm and 560 nm.

**Plasma oxidized low density lipoprotein and malondialdehyde**

Plasma oxidized LDL (ox-LDL) was measured using an enzyme immunoassay (Mercodia, Uppsala, Sweden) [15]. The resulting color reaction was measured using the iMark™ microplate absorbance reader (Bio-Rad Laboratories, Hercules, CA, USA). The wavelength correction was set to 450 nm and 540 nm. The intra-assay and inter-assay coefficients of variance were 6.30% and 8.20%, respectively. Plasma malondialdehyde (MDA) was measured from thiobarbituric acid-reactive substances using the TBARS Assay Kit (Cell Biolabs, Inc. Sand Diego, CA, USA) [17]. The resulting color reaction was measured at a wavelength of 530 nm using the iMark™ microplate absorbance reader (Bio-Rad Laboratories, Hercules, CA, USA).

**Liver and kidney functions, blood hemoglobin, and platelet counts**

Serum aspartate aminotransferase and alanine aminotransferase levels were measured by a Modified IFCC UV method. Serum creatinine was measured by a kinetic colorimetric assay (Jaffe). Serum blood urea nitrogen concentrations were measured by a Kinetic UV Assay. Hemoglobin and platelet counts in whole blood were determined using the HORIBA ABX diagnostic (HORIBA ABX SAS, Parc Euromedicine, Montpellier, France).

**Assessment of dietary intake**

Information about habitual food intake was obtained using a 24-hour recall method and a semi-quantitative food frequency questionnaire, which was previously validated [18]. We used the former to carry out analyses and the latter to determine whether the data collected by the recall method were representative of the dietary patterns. A registered dietician gave all the participants written and verbal instructions on how to complete a 3-day (two weekdays and one weekend day) dietary record. Dietary energy values and nutrient content from the 3-day food records were calculated using the Computer Aided Nutritional Analysis program (CAN-pro 3.0, Korean Nutrition Society, Seoul, Korea). Total energy expenditure (TEE, kcal/day) was calculated from activity patterns including the basal metabolic rate and physical activity over 24 h [19] and considering the thermic effect of food. The basal metabolic rate for each participant was calculated using the Harris-Benedict equation [20].

**Statistical analysis**

Statistical analyses were performed with Win SPSS ver. 21.0 (SPSS Inc., Chicago, IL, USA). Differences in continuous variables among subgroups were tested using an independent t-test or a one-way ANOVA followed by Bonferroni corrections. Non-continuous variables were tested with a chi-square test. A general linear model analysis (post-hoc multiple comparison tests) followed by a Bonferroni correction was also used to compare subgroups with adjustment for confounders (i.e., age, gender, cigarette smoking, alcohol drinking, and/or BMI). Pearson and partial correlation analyses were performed for the relationships among the variables. Multiple regression analysis was used to find the major determinants for cerebrovascular risk. Skewed variables were log transformed for statistical analysis. For descriptive pur-
poses, mean values were presented using untransformed values. Results were expressed as means ± SE or percentages. A two-tailed \( p \)-value < 0.05 was considered statistically significant.

## Results

### General characteristics of study participants

Table 1 presents the general characteristics of the study participants. The patients with stroke were older, had higher systolic BP and consumed less protein, and higher polyunsaturated fatty acid to saturated fatty acid ratio (PUFA/SFA) compared with the control individuals \( (p < 0.001 \text{ for each factor}) \). The patients with stroke had a higher proportion of males and a lower proportion of current alcohol drinkers compared with the control individuals \( (p < 0.0001) \). All of the patients with stroke were taking an antplatelet agent, and 75.6\% of them were taking antihypertensive and lipid-lowering drugs.

### Basic biochemical parameters, lipid profiles, oxidative stress, and inflammatory markers

The patients with stroke had higher fasting levels of glucose, HbA1c (\%), and triglyceride and lower levels of HDL-, LDL-, and total cholesterol compared with the control individuals (Table 2). The lipid-lowering drugs that the patients with stroke consumed might influence the levels of LDL- and total cholesterol. The levels of inflammatory markers (hs-CRP, TNF-\( \alpha \), and IL-6) were significantly higher in the patients with stroke than in the control individuals, but the levels of oxidative stress markers (ox-LDL and MDA-TBARS) were not significantly dif-

### Table 1. General characteristics of the study participants

|                          | Control individuals \((n = 112)\) | Patients with stroke \((n = 41)\) | \( P \) |
|--------------------------|-----------------------------------|----------------------------------|--------|
| Age, years               | 48.3 ± 0.99                       | 66.7 ± 1.35                     | < 0.0001 |
| Body mass index, kg/m\(^2\) | 23.3 ± 0.32                      | 23.6 ± 0.04                     | n.s.   |
| Systolic BP, mmHg        | 113.5 ± 1.05                      | 128.6 ± 2.36                    | < 0.0001 |
| Diastolic BP, mmHg       | 71.7 ± 0.65                       | 71.7 ± 1.68                     | n.s.   |
| Current smokers, n, %    | 4 (3.6)                           | 2 (5.0)                         | n.s.   |
| Current drinkers, n, %   | 70 (62.5)                         | 6 (15.0)                        | < 0.0001 |
| Male, n, %               | 21 (18.8)                         | 23 (56.1)                       | < 0.0001 |
| Obesity*, n, %           | 34 (30.4)                         | 12 (29.3)                       | n.s.   |
| Medications, %           |                                   |                                 |        |
| Antplatelet              | -                                 | 100                              | -      |
| Antihypertensive         | -                                 | 75.6                             | -      |
| Lipid-lowering           | -                                 | 75.6                             | -      |
| Dietary intake and energy expenditure | | | |
| TEE/TEI                  | 0.95 ± 0.28                       | 0.97 ± 0.24                     | n.s.   |
| Carbohydrate, % of TEI   | 58.8 ± 0.75                       | 62.6 ± 1.73                     | n.s.   |
| Fat, % of TEI            | 24.1 ± 0.64                       | 22.1 ± 1.46                     | n.s.   |
| Protein, % of TEI        | 17.2 ± 0.30                       | 15.4 ± 0.55                     | 0.003  |
| PUFA/SFA                 | 1.48 ± 0.84                       | 2.10 ± 1.07                     | < 0.001 |
| Fiber, g/day             | 22.4 ± 0.76                       | 24.0 ± 1.60                     | n.s.   |

Data are means ± S.E. or percentage (%). \( p \)-values tested by Student’s \( t \)-test. n.s. indicates not statistically significant. BP: blood pressure, TEE: total energy expenditure (kcal/day), TEI: total energy intake (kcal/day), PUFA: polyunsaturated fatty acid (g/day), SFA: saturated fatty acid (g/day). *Obesity: body mass index ≥ 25 kg/m\(^2\).
ferent between the two groups, which may be also related with the effect of lipid lowering drugs. In addition, other basic biochemical parameters such as hemoglobin, platelet counts, liver functions (aspartate aminotransferase and alanine aminotransferase), and kidney functions (creatinine and blood urea nitrogen) were not significantly different between the patients with stroke and the control individuals.

### Relationship between fasting glucose and oxidative stress/inflammatory markers

Figure 1 presents the correlations of fasting glucose level with oxidative stress and inflammation status. The fasting glucose level was positively correlated with the levels of ox-LDL (r = 0.172, p < 0.05) and MDA (r = 0.246, p < 0.001). These relationships were maintained after adjustments for age and gender (r = 0.173, p < 0.05 for ox-LDL; r = 0.251, p < 0.001 for MDA). The statistical significances were still maintained (r = 0.200, p < 0.05 for MDA) and at least turned to a trend (r = 0.164, p < 0.1 for ox-LDL) after further adjustments for cigarette smoking, alcohol consumption, and BMI (Figure 1). In addition, the fasting glucose level was positively correlated with the levels of hs-CRP (r = 0.301, p < 0.0001), TNF-α (r = 0.233, p < 0.001), and IL-6 (r = 0.240, p < 0.001). The statistical significance was maintained (r = 0.310, p < 0.0001 and r = 0.293, p < 0.001 for hs-CRP) and at least turned to a trend (r = 0.153, p < 0.1 and r = 0.143, p < 0.1 for TNF-α; r = 0.167, p < 0.1 and r = 0.158, p < 0.1 for IL-6) after adjustment for confounding factors (Figure 1).

### Association of fasting glycemic status with cerebrovascular risk by multiple regression analysis

A multiple stepwise regression analysis was performed to identify the association of fasting glycemic status with cerebrovascular risk. Input factors were age, gender, BMI, BP, triglyceride, total cholesterol, LDL-cholesterol, HDL-cholesterol, fasting glucose, HbA1C, hs-CRP, TNF-α, IL-6, ox-LDL, malondialdehyde, dietary PUFA/SFA, TEE/TEI, cigarette smoking and alcohol consumption which were closely related with meta-

---

**Table 2. Basic biochemical parameters, oxidative stress, and inflammatory markers in control individuals and patients with stroke**

|                     | Control individuals (n = 112) | Patients with stroke (n = 41) | P   |
|---------------------|-------------------------------|-------------------------------|-----|
| Glucose, mg/dL      | 90.6 ± 1.13                   | 99.3 ± 2.96                   | 0.007|
| HbA1C, %            | 5.31 ± 0.04                   | 5.90 ± 0.15                   | < 0.0001|
| Triglyceride, mg/dL | 96.6 ± 6.41                   | 132.3 ± 12.7                  | 0.001|
| HDL-cholesterol, mg/dL | 63.5 ± 1.46               | 46.6 ± 1.95                   | < 0.0001|
| LDL-cholesterol, mg/dL | 122.4 ± 3.00               | 104.9 ± 5.77                  | 0.004|
| Total cholesterol, mg/dL | 194.0 ± 3.17              | 169.2 ± 6.86                  | < 0.0001|
| hs-CRP, mg/dL       | 0.63 ± 0.15                   | 2.26 ± 0.86                   | < 0.0001|
| TNF-α, pg/ml        | 1.26 ± 0.13                   | 1.79 ± 0.22                   | 0.001|
| IL-6, pg/ml         | 1.00 ± 0.09                   | 1.47 ± 0.20                   | 0.001|
| Oxidized LDL, U/L   | 57.5 ± 1.89                   | 54.6 ± 2.60                   | n.s.|
| MDA-TBARS, mM       | 28.5 ± 1.78                   | 23.9 ± 1.70                   | n.s.|
| Hemoglobin, g/dL    | 13.8 ± 0.13                   | 13.7 ± 0.28                   | n.s.|
| Platelet, ×10⁹/L    | 261.8 ± 5.50                  | 263.4 ± 16.5                  | n.s.|
| AST, U/L            | 26.0 ± 0.78                   | 23.5 ± 0.95                   | n.s.|
| ALT, U/L            | 23.1 ± 1.29                   | 19.2 ± 1.40                   | n.s.|
| Creatinine, mg/dL   | 0.81 ± 0.03                   | 0.91 ± 0.08                   | n.s.|
| BUN, mg/dL          | 13.5 ± 0.39                   | 15.4 ± 1.02                   | n.s.|

Data are means ± S.E. n.s. indicates not statistically significant.

HDL: high density lipoprotein, LDL: low density lipoprotein, hs-CRP: high-sensitivity C-reactive protein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, MDA-TBARS: malondialdehyde-thiobarbituric acid-reactive substances, AST: aspartate aminotransferase, ALT: alanine aminotransferase, BUN: blood urea nitrogen.

* Tested after log-transformation, p-values tested by Student’s t-test.
bolic syndrome, cardio- and cerbro-vascular diseases. Fasting glucose and HbA1C were found main contributors to cerebro-vascular risk (adjusted $\beta$-coefficients $[\beta]$) for fasting glucose: 0.284, $p < 0.0001$; for HbA1C [%]: 0.149, $p < 0.044), together with age, systolic BP, total cholesterol, hs-CRP, BMI, dietary PUFA/SFA intake ($r^2 = 0.634, p = 0.044$).

**Basic parameters and lipid profiles according to fasting glucose status**

Based on the above results, the study participants were subdivided by fasting glucose status (normal fasting glucose [NFG: 70–99 mg/dL]; higher fasting glucose [HFG: 100–125 mg/dL]), resulting in four groups: control-NFG ($n = 91$), control-HFG ($n = 21$), stroke-NFG ($n = 27$), and stroke-HFG ($n = 14$). The average time since being diagnosed with stroke was not statistically different between the stroke-NFG and stroke-HFG groups ($4.73 \pm 0.83$ years and $4.54 \pm 0.89$ years, respectively). Among the control individuals, the HFG group showed higher levels of BMI, triglyceride, LDL-cholesterol, and total cholesterol, and lower levels of HDL-cholesterol compared with the NFG group. Among the patients with stroke, the HFG group showed significantly higher levels of LDL-cholesterol and consumed a lower dietary PUFA/SFA compared with the NFG group. In addition, serum triglyceride and total cholesterol levels tended to be higher in the stroke-HFG group compared with those in the stroke-NFG group, but those differences did not reach a statistical significance (Table 3).

**Association of fasting glucose with oxidative stress**

Figure 2 shows the fasting glucose-associated plasma levels of ox-LDL and MDA after adjustments for age, gender, cigarette smoking, alcohol consumption, and BMI. Plasma levels of ox-LDL ($p < 0.05$) and MDA ($p < 0.01$) were significantly higher in the control-HFG group than in the control-NFG group. The levels of ox-LDL and MDA tended to be higher in the stroke-HFG group compared with those in the stroke-NFG group (p...


Table 3. Basic parameters and lipid profiles according to fasting glucose status in control individuals and patients with stroke

|                          | Control individuals (NFG (n = 91)) | Patients with stroke (HFG (n = 21)) | P       |
|--------------------------|------------------------------------|-------------------------------------|---------|
| Glucose, mg/dL<sup>a</sup> | 86.0 ± 0.72<sup>a</sup>             | 110.3 ± 1.97<sup>b</sup>            | 88.9 ± 1.46<sup>b</sup> | 119.4 ± 4.86<sup>b</sup> | < 0.0001 |
| HbA1C, %                 | 5.22 ± 0.04<sup>a</sup>             | 5.69 ± 0.08<sup>ab</sup>            | 5.52 ± 0.09<sup>ab</sup> | 6.64 ± 0.32<sup>bc</sup> | < 0.0001 |
| Age, years               | 47.6 ± 1.16<sup>a</sup>             | 51.0 ± 1.60<sup>b</sup>             | 65.8 ± 1.88<sup>b</sup> | 68.5 ± 1.51<sup>b</sup> | < 0.0001 |
| Body mass index, kg/m²   | 22.8 ± 0.32<sup>a</sup>             | 25.5 ± 0.84<sup>b</sup>             | 23.4 ± 0.47<sup>b</sup> | 24.1 ± 0.76<sup>b</sup> | 0.009    |
| Systolic BP, mmHg        | 112.6 ± 1.19<sup>a</sup>            | 117.4 ± 2.02<sup>b</sup>            | 129.5 ± 2.95<sup>b</sup> | 126.8 ± 4.02<sup>b</sup> | < 0.0001 |
| Diastolic BP, mmHg       | 71.0 ± 0.70                          | 74.6 ± 1.56                          | 73.8 ± 2.21                          | 67.8 ± 2.16                          | n.s.     |
| Triglyceride, mg/dL<sup>b</sup> | 85.5 ± 5.91<sup>b</sup>           | 145.0 ± 19.8<sup>b</sup>            | 127.3 ± 14.7<sup>b</sup>          | 142.1 ± 24.7<sup>b</sup>          |         |
| HDL-cholesterol, mg/dL   | 65.5 ± 1.66<sup>a</sup>             | 55.0 ± 2.25<sup>b</sup>             | 45.8 ± 2.37<sup>b</sup>          | 48.1 ± 3.53<sup>b</sup>          | < 0.0001 |
| LDL-cholesterol, mg/dL   | 118.3 ± 3.05<sup>b</sup>            | 140.3 ± 8.09<sup>bc</sup>           | 101.4 ± 6.80<sup>bc</sup>         | 111.6 ± 10.8<sup>bc</sup>         | 0.003    |
| Total cholesterol, mg/dL | 189.5 ± 3.14<sup>a</sup>            | 213.3 ± 9.05<sup>a</sup>            | 163.1 ± 7.73<sup>a</sup>          | 180.9 ± 13.3<sup>a</sup>          | < 0.0001 |
| TEE/TEI                  | 0.97 ± 0.03                         | 0.90 ± 0.06                          | 0.95 ± 0.04                          | 1.03 ± 0.08                          | n.s.     |
| Carbohydrate, %          | 58.5 ± 0.85                         | 59.8 ± 1.61                          | 62.5 ± 2.29                          | 62.7 ± 2.92                          | n.s.     |
| Fat, %                   | 24.4 ± 0.73                         | 22.7 ± 1.36                          | 21.9 ± 1.88                          | 22.5 ± 0.61                          | n.s.     |
| Protein, %               | 17.1 ± 0.34<sup>a</sup>             | 17.5 ± 0.62<sup>b</sup>             | 15.6 ± 0.72<sup>b</sup>            | 14.8 ± 0.81<sup>b</sup>            | 0.025    |
| PUFA/SFA                 | 1.46 ± 0.09<sup>a</sup>             | 1.54 ± 0.18<sup>b</sup>             | 2.01 ± 0.27<sup>b</sup>            | 1.64 ± 0.08<sup>b</sup>            | 0.003    |
| Fiber, g/day             | 21.8 ± 0.83                         | 24.8 ± 1.81                          | 24.7 ± 1.77                          | 22.4 ± 3.35                          | n.s.     |

<sup>a</sup> Tested after log-transformation. Tested by one-way analysis of variance followed by Bonferroni correction.

Association of fasting glucose with inflammation status

Figure 3 presents the fasting glucose-associated inflammatory status (hs-CRP, TNF-α, and IL-6 levels) in the control individuals and the patients with stroke after adjustments for age, gender, cigarette smoking, alcohol consumption and BMI. Plasma levels of hs-CRP, TNF-α and IL-6 were not significantly different between control-NFG group and stroke-NFG group (Figure. 3). The plasma levels of hs-CRP and TNF-α were significantly higher in the HFG groups compared with those in the corresponding NFG groups (p < 0.05 for each comparison in the control individuals, p < 0.001 for each comparison in the patients with stroke). The IL-6 levels were significantly higher in the stroke-HFG group compared with those in the stroke-NFG group (p < 0.01), but they were not significantly different between the control-HFG and control-NFG groups. In addition, all the inflammatory levels were remarkably the highest in the stroke-HFG group among the four subgroups.

Discussion

The aim of this present study was to investigate the association between fasting glycemic status and cerebrovascular risk parameters including classical parameters, oxidative and inflammatory markers in non-diabetic Koreans. Multiple regression analysis revealed that fasting glycemic status particularly, fasting glucose was found a main contributor to cerebrovascular risk. We also found evidences that oxidative stress and inflammation status might mediate the mechanisms by which fasting glucose increases the cerebrovascular risk. As initially hypothesized, our results suggest that fasting glucose status may be a useful indicator for cerebrovascular risk in non-diabetic Koreans.

Several cohort and cross-sectional studies have reported an association between glucose levels and cerebrovascular risk parameters including classical parameters, oxidative and inflammatory markers in non-diabetic Koreans. Multiple regression analysis revealed that fasting glycemic status particularly, fasting glucose was found a main contributor to cerebrovascular risk. We also found evidences that oxidative stress and inflammation status might mediate the mechanisms by which fasting glucose increases the cerebrovascular risk. As initially hypothesized, our results suggest that fasting glucose status may be a useful indicator for cerebrovascular risk in non-diabetic Koreans.
glucose levels and the risk of stroke in patients with diabetes and impaired fasting glucose status [5-8,21-23]; for example, the findings of the Northern Manhattan Study show a strong relationship between fasting glucose levels and increased risk of stroke in diabetic patients even after adjustments for other vascular risk factors [7]. Rundek et al. reported that insulin resistance estimated by the homeostasis model assessment could be used as a marker for increased risk of ischemic stroke [8].

A higher concentration of blood glucose results in the production of ROS [9], and the reaction of glucose with blood proteins forms glycation end products, which can also trigger the production of ROS [9,10]. Consequently, the ROS can initiate a chain reaction leading to an increased inflammatory pathway.

**Figure 2.** Association of fasting glucose and oxidative stress status in control individuals and patients with stroke. Values are presented as means ± standard errors. Tested after log-transformation. (n) indicates the number of subjects in each group; tested by a general linear model followed by Bonferroni correction with adjustments for age, gender, cigarette smoking, alcohol consumption, and body mass index. NFG: 70–99 mg/dL, HFG: 100–125 mg/dL. *p<0.1; †p<0.05; ‡p<0.001, compared with the corresponding NFG control individuals or patients with stroke; §p<0.05, compared with HFG control individuals.

**Figure 3.** Association of fasting glucose and inflammation status in control individuals and patients with stroke. Values are presented as means ± standard errors. Tested after log transformation. (n) indicates the number of individuals in each group; tested by a general linear model followed by Bonferroni correction with adjustments for age, gender, cigarette smoking, alcohol consumption, and body mass index. NFG: 70–99 mg/dL, HFG: 100–125 mg/dL. hs-CRP: high-sensitivity C-reactive protein, IL-6: interleukin-6, TNF-α: tumor necrosis factor-alpha. *p<0.05; †p<0.001; compared with the corresponding NFG control individuals or patients with stroke; §p<0.05, compared with NFG control individuals; ‡p<0.05, compared with HFG control individuals.
response, the chemical modification of lipoproteins, and a reduction of nitric oxide availability, thereby increasing the risk of atherogenesis in the blood vessels and brain [9-12]. Several in vitro studies have demonstrated the increased expression of oxidative stress markers in cells exposed to fluctuating glucose concentrations [10-12]. Clinical trials also reported that a greater frequency and magnitude of glycemic excursions in conventionally treated patients compared with those in intensively treated patients might increase glycemic variability, generating more ROS and leading to inflammation and vascular damage [9,10].

In our study, the inflammatory status expressed by hs-CRP, IL-6, and TNF-α were higher in patients with stroke than in control individuals. On the other hand, oxidative stress expressed by ox-LDL and MDA was not statistically significantly different between the two groups, which may be affected by lipid-lowering drugs (i.e., statins) that strongly attenuate not only lipid levels in blood but also lipid oxidation. Nevertheless, the correlation analyses revealed that those inflammatory and oxidative stress parameters were positively correlated with fasting glucose levels and those relationships were statistically significant after adjustments, although some of the significant results were reduced to trends. Furthermore, even though all of the individuals were non-diabetic, those with HFG showed higher oxidative stress levels and inflammation status than their counterparts with NFG. In particular, the patients with stroke and HFG had the highest inflammatory levels among the four subgroups. Those results suggest that fasting glycemic control is important not only for non-diabetic individuals with no history of stroke, but also for non-diabetic individuals with a history of stroke who are using medication to prevent the recurrence of stroke or further complications.

In addition, we found that control individuals and patients with stroke had different patterns of dietary protein intake and PUFA/SFA. Stroke patients consumed a lower proportion of protein and a higher PUFA/SFA compared with control individuals. It is possible that, acting on the advice of dietitians since being diagnose with stroke, the patients with stroke paid more attention to their dietary intake in order to manage their health status and prevent recurrence of their diseases or complications, and therefore consumed less protein- and SFA-sourced foods (mainly animal-sourced foods) and more PUFA-sourced foods (mainly fish and plant-sourced foods). In fact, many studies have reported an association between dietary intake and glycemic control, insulin resistance, oxidative stress, and inflammatory processes, and consequently the risk or development of diseases [16,24-26]. Recent studies have reported protective effects of blood or dietary PUFAs, particularly n-3 PUFAs on cardiovascular health, although the results are still controversial [24-27]. In our previous studies, PUFAs, particularly docosahexaenoic acid (DHA), helped to suppress vascular proliferation and inflammation [16], and serum phospholipid DHA composition were inversely associated with the risk of intracranial atherosclerotic stenosis [26], suggesting that sufficient amounts of DHA in the plasma or in the diet could reduce the risk of intracranial atherosclerotic stenosis. In a sub-analysis in our current study, the patients with stroke and NFG were consuming a higher ratio of PUFA/SFA and showed significantly lower inflammatory levels compared with their counterparts with HFG. Interestingly, the inflammatory levels in the individuals with stroke and NFG were similar to those in the controls with no history of stroke, but the inflammatory levels in the patients with stroke and HFG were the highest among the four subgroups. Based on those results, we assumed that dietary intake, and particularly PUFA intake, might be involved in fasting glycemic control and partly contribute to the regulation of oxidative stress and inflammation.

One limitation of this study is that it did not allow for the sequential assessment of a direct association between fasting glucose and cerebrovascular risk in non-diabetic individuals, because the exposure and outcome data were collected at a single time point. Further investigation through longitudinal studies will help confirm the status of fasting glycemic control as an early predictor of cerebrovascular risk, in association with oxidative stress and inflammatory status in non-diabetic control individuals, and with complications or recurrence of stroke in patients with a prior history of stroke. In addition, a dietary intervention study is needed to further elucidate the effects of dietary modification on the relationship between early glycemic control and cerebrovascular risk.

Conclusion

This study suggests that fasting glucose status may be a useful indicator for cerebrovascular risk in non-diabetic individuals. Oxidative stress and inflammation status might also mediate the mechanisms by which fasting glucose levels increase cerebrovascular risk in non-diabetic status.

Acknowledgements

We thank the research volunteers who participated in the study described in this manuscript. This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of
Conflict of Interest
All authors declare no conflict of interest.

Authors’ contributions
All the authors were involved in the development of the study protocol and the experimental design. All the authors read, commented on, and contributed to the submitted manuscript. Sample collection and experiments were performed by JHL, SRY, GYN, MJ, MRA, JKC and OYK. Data were analyzed by JHL, SRY, GYN and OYK. The manuscript was written by JHL and OYK, and finalized by OYK. None of the authors have any conflicts of interest in relation to the materials presented in this paper.

ORCID
Oh Yoen Kim  http://orcid.org/0000-0001-9262-3309

References
1. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis 2013;1:1-2.
2. Centers for Disease Control and Prevention (US). National Center for Health Statistics. Leading causes of death [Internet]. Available from: http://www.cdc.gov/rehs/fastats/crd.htm. [cited 2013 June 20]. 2013.
3. World Health Organization; World Heart Federation; World Stroke Organization. Global atlas on cardiovascular disease prevention and control. Mendis S, Puska P, Norrving B, editors. Geneva: World Health Organization; 2011.
4. Statistics Korea. Cause of death statistics in 2013. Daejeon: Statistics Korea; 2014.
5. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004;35:2351-5.
6. Nielsen C, Fleming RM. Blood glucose and cerebrovascular disease in nondiabetic patients. Angiology 2007;58:625-9.
7. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 2008;31:1132-7.
8. Rundek T, Gardener H, Xu Q, Goldberg RB, Wright CB, Boden-Albala B, Disla N, Paik MC, Elkind MS, Sacco RL. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch Neurol 2010;67:1195-200.
9. Wright E Jr, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006;60:308-14.
10. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804.
11. Schiekofer S, Andressy M, Chen J, Rudoyfsky G, Schneider J, Wendt T, Stefan N, Humpert F, Fritsche A, Stumvoll M, Schleicher E, Häring HU, Nawroth PP, Bierhaus A. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003;52:621-33.
12. Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulo-interstitial cells. Diabetologia 1999;42:1113-9.
13. Chae JS, Kim OY, Paik JK, Kang R, Seo WJ, Jeong TS, Sweeney G, Lee SH, Lee JH. Association of Lp-PLA2 activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. Atherosclerosis 2011;218:499-506.
14. Ohnuki Y, Nagano R, Takizawa S, Takagi S, Miyata T. Advanced glycation end products in patients with cerebral infarction. Intern Med 2009;48:87-91.
15. Kim OY, Lim HH, Lee MJ, Kim JY, Lee JH. Association of fatty acid composition in serum phospholipids with metabolic syndrome and arterial stiffness. Nutr Metab Cardiovasc Dis 2013;23:366-74.
16. Song J, Kwon N, Lee MH, Ko YG, Lee JH, Kim OY. Association of serum phospholipid PUFA with cardiometabolic risk: beneficial effect of DHA on the suppression of vascular proliferation/inflammation. Clin Biochem 2014;47:361-8.
17. Kwak JH, Paik JK, Kim HJ, Kim OY, Shin DY, Kim HJ, Lee JH, Lee JH. Dietary treatment with rice containing resistant starch improves markers of endothelial function with reduction of postprandial blood glucose and oxidative stress in patients with prediabetes or newly diagnosed type 2 diabetes. Atherosclerosis 2012;224:457-64.
18. Shim JS, Oh KW, Suh I. A study on validity of a 299 semi-quantitative food frequency questionnaire of Korean adults. Korean J Community Nutr 2002;7:484-94.
19. Christian JL, Greger JL. Nutrition for living. Redwood City (CA): Benjamin Cummings; 1994.
20. The American Dietetic Association. Handbook of clinical dietetics. 2nd ed. New Haven (CT): Yale University Press; 1992.
21. Sung J, Song YM, Ebrahim S, Lawlor DA. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009;119:812-9.
22. Cao W, Ling Y, Wu F, Yang L, Cheng X, Dong Q. Higher fasting glucose next day after intravenous thrombolysis is independently associated with poor outcome in acute ischemic stroke. J Stroke Cerebrovasc Dis 2015;24:100-3.
23. Vermeer SE, Sandee W, Algra A, Koudstaal PJ, Kappelle LJ, Dippel DW; Dutch TIA Trial Study Group. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006;37:1413-7.
24. Larsson SC, Virtamo J, Wolk A. Dietary fats and dietary cholesterol and risk of stroke in women. Atherosclerosis 2012;221:282-6.
25. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67.
26. Kim YJ, Kim OY, Cho Y, Chung JH, Jung YS, Hwang GS, Shin MJ. Plasma phospholipid fatty acid composition in ischemic stroke: importance of docosahexaenoic acid in the risk for intracranial atherosclerotic stenosis. Atherosclerosis 2012;225:418-24.
27. Yakooob MY, Shi P, Hu FB, Campos H, Rxedre KM, Orav EJ, Willett WC, Mozaffarian D. Circulating biomarkers of dairy fat and risk of incident stroke in U.S. men and women in 2 large prospective cohorts. Am J Clin Nutr 2014;100:1437-47.